Iterum Therapeutics PLC (NASDAQ:ITRM) Receives Average Recommendation of “Buy” from Analysts

Shares of Iterum Therapeutics PLC (NASDAQ:ITRM) have been assigned a consensus rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $18.00.

ITRM has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating on shares of Interpace Diagnostics Group in a research note on Friday, June 21st. Royal Bank of Canada boosted their price target on shares of WestJet Airlines from C$20.00 to C$31.00 and gave the stock a “sector perform” rating in a research note on Wednesday, May 15th. Finally, Zacks Investment Research lowered shares of H&E Equipment Services from a “hold” rating to a “sell” rating in a research note on Wednesday, July 17th.

Shares of ITRM stock traded up $0.06 on Friday, hitting $6.64. The company has a 50-day simple moving average of $6.70. Iterum Therapeutics has a 12-month low of $4.70 and a 12-month high of $11.22. The company has a current ratio of 4.36, a quick ratio of 4.36 and a debt-to-equity ratio of 0.24. The firm has a market cap of $92.69 million, a PE ratio of -0.93 and a beta of 2.06.

Iterum Therapeutics (NASDAQ:ITRM) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.35) by ($0.09). The business had revenue of $0.04 million for the quarter. Iterum Therapeutics had a negative return on equity of 83.95% and a negative net margin of 11,956.64%. As a group, equities analysts predict that Iterum Therapeutics will post -6.43 earnings per share for the current year.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Featured Story: What is a management fee?

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with's FREE daily email newsletter.